EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a combination therapy consisting of Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) and Yervoy (ipilimumab) for the first-line …